FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma By Ogkologos - March 25, 2026 117 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR Experimental Drug Prevents Doxorubicin from Harming the Heart April 6, 2020 Quitting Smoking Improves Survival in People with Lung Cancer September 14, 2021 New drug combo for advanced breast cancer approved for NHS in... August 12, 2021 EMA Recommends a Change to the Terms of the Marketing Authorisation... October 23, 2025 Load more HOT NEWS FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection A Large Genomic Analysis Identifies That Persistent Tumour Mutational Burden Is... Διαφημιστείτε Determination of the Incidence of Driver Mutations in Patients with NSCLC...
